Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

October 6, 2017: By Jon Swedien

AerieAerie Pharmaceuticals announced Oct. 5 that it has acquired from Envisia Therapeutics the rights to use its PRINT technology in ophthalmology, along with certain other assets.

The PRINT technology is Envisia’s proprietary system for sustained-release products.

Under the terms of the agreement, Envisia will receive $25 million upfront in a combination of cash and Aerie common stock. Envisia, of Durham, North Carolina, could earn more based on certain product approval milestones, Aerie said.

Aerie, of Irvine, California, said it intends to use the technology to accelerate the advancement of its pipeline to treat conditions in the back of the eye, such as wet age-related macular degeneration and diabetic retinopathy.

Aerie’s initial focus will be in using PRINT to manufacture injectable implants containing its preclinical product candidate known as AR-13154, a potential wet AMD treatment.

This potentially could be done in conjunction with a biodegradable polymer from DSM, a Netherlands-based company that Aerie struck a collaborative agreement with in July.

In addition, Aerie acquired the intellectual property rights relating to ENV1105, Envisia’s preclinical dexamethasone steroid product candidate for the treatment of diabetic macular edema, which also uses the PRINT technology, Aerie said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023